Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Mikhaylov D, Glickman JW, Del Duca E, Nia J, Hashim P, Singer GK, Posligua AL, Florek AG, Ibler E, Hagstrom EL, Estrada Y, Rangel SM, Colavincenzo M, Paller AS, Guttman-Yassky E. Mikhaylov D, et al. Among authors: nia j. Arch Dermatol Res. 2023 Mar;315(2):181-189. doi: 10.1007/s00403-022-02336-0. Epub 2022 Mar 1. Arch Dermatol Res. 2023. PMID: 35230488 Clinical Trial.
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis.
Ungar B, Pavel AB, Li R, Kimmel G, Nia J, Hashim P, Kim HJ, Chima M, Vekaria AS, Estrada Y, Xu H, Peng X, Singer GK, Baum D, Mansouri Y, Taliercio M, Guttman-Yassky E. Ungar B, et al. Among authors: nia j. J Allergy Clin Immunol. 2021 Jan;147(1):394-397. doi: 10.1016/j.jaci.2020.04.055. Epub 2020 May 16. J Allergy Clin Immunol. 2021. PMID: 32428528 Clinical Trial. No abstract available.
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
Bagel J, Blauvelt A, Nia J, Hashim P, Patekar M, de Vera A, Ahmad K, Paguet B, Xia S, Muscianisi E, Lebwohl M. Bagel J, et al. Among authors: nia j. J Eur Acad Dermatol Venereol. 2021 Jan;35(1):135-142. doi: 10.1111/jdv.16558. Epub 2020 Jun 8. J Eur Acad Dermatol Venereol. 2021. PMID: 32365251 Free PMC article. Clinical Trial.
Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial.
Hashim PW, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, Chen T, Genece J, Baum D, Kimmel GW, Nia JK, Gagliotti M, Lebwohl MG. Hashim PW, et al. Among authors: nia jk. J Am Acad Dermatol. 2020 Feb;82(2):360-365. doi: 10.1016/j.jaad.2019.06.1288. Epub 2019 Jul 3. J Am Acad Dermatol. 2020. PMID: 31279028 Clinical Trial.
Nanoparticles in dermatologic surgery.
Hashim PW, Nia JK, Han G, Ratner D. Hashim PW, et al. Among authors: nia jk. J Am Acad Dermatol. 2020 Oct;83(4):1144-1149. doi: 10.1016/j.jaad.2019.04.020. Epub 2019 Apr 13. J Am Acad Dermatol. 2020. PMID: 30991121 Review.
28 results